COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
NCT04369066 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1971
Last updated 2025-09-23
Summary
This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time.
After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.
The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0 (day of inclusion), between 6 weeks and 3 months ,6 months and 12 months post-inclusion.
Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples.
The nasopharyngeal swabs will be performed at 3 times: , between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff who have had at least one of the following four criteria on the sample or questionnaire carried out at T0:
* have had RT-PCR+
* and/or presence of antibodies at the 95% threshold
* and/or anosmia/ageusia
* and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the four criteria above, a nasopharyngeal swab will be performed during the following visits.
The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses.
If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months, 6 months and 12 months after inclusion.
For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples and nasopharyngeal swabs shall be performed.
Those shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.
The blood samplings and nasopharyngeal swabs will be performed at 4 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, at 6 months and 12 months post-inclusion
Conditions
- Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection
Interventions
- DIAGNOSTIC_TEST
-
Blood samples (collection of 5 mL of blood in a dry tube)
A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data. The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion. For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks. The serum samples will be extracted and collected prospectively from the blood samples. For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie.
- DIAGNOSTIC_TEST
-
Nasopharyngeal swabs
The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs. The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers). For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks. The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total.
Sponsors & Collaborators
-
Institut Curie
lead OTHER
Principal Investigators
-
Pierre Fumoleau, PhD · Institut Curie
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-04-28
- Primary Completion
- 2022-01-06
- Completion
- 2022-05-13
Countries
- France
Study Locations
More Related Trials
-
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
NCT04664023 ·Status: COMPLETED
-
Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection
NCT05000307 ·Status: COMPLETED ·Phase: NA
-
Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)
NCT04355351 ·Status: COMPLETED ·Phase: NA
-
Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19
NCT04355533 ·Status: COMPLETED ·Phase: NA
-
COVID-19 Serologies Among Healthcare Workers at CHSD (SERO2)
NCT06989307 ·Status: COMPLETED
-
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.
NCT04322279 ·Status: TERMINATED
-
COVID 19-Caregivers IGg Seroconversion
NCT04353323 ·Status: UNKNOWN
-
Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
NCT04550390 ·Status: COMPLETED
-
Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers
NCT04445415 ·Status: UNKNOWN
-
Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection
NCT04750720 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen
NCT04707833 ·Status: TERMINATED ·Phase: NA
-
Prospective Clinical and Virological Analysis of Healthcare Workers Diagnosed Positive for Covid-19.
NCT04858581 ·Status: UNKNOWN ·Phase: NA
-
Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff
NCT04896788 ·Status: UNKNOWN ·Phase: NA
-
RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19
NCT04397666 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
NCT04568044 ·Status: ACTIVE_NOT_RECRUITING
-
Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP)
NCT04418375 ·Status: COMPLETED
-
Serology COVID-19 From the Cornwall Hospital Union
NCT04363593 ·Status: COMPLETED ·Phase: NA
-
Detection of COVID-19 in Saliva Collection
NCT04386551 ·Status: COMPLETED
-
Covid-19 Rapid Diagnostic Tests on Blood Drop
NCT04467008 ·Status: COMPLETED
-
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition
NCT04573634 ·Status: WITHDRAWN
-
Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19
NCT04418206 ·Status: COMPLETED ·Phase: NA
-
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients
NCT05905380 ·Status: UNKNOWN
-
Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers
NCT04525417 ·Status: COMPLETED ·Phase: NA
-
Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection
NCT04624997 ·Status: UNKNOWN
-
COVID-19 Prevalence in UNIVI Geriatric Institutions: Epidemiological Study of Immunological Status With Rapid Serological Tests
NCT04790994 ·Status: UNKNOWN